Institut für Virologie, Philipps-Universität Marburg, Hans-Meerwein-Str. 2, 35043 Marburg, Germany.
J Gen Virol. 2010 May;91(Pt 5):1325-34. doi: 10.1099/vir.0.018226-0. Epub 2010 Jan 13.
The highly pathogenic Marburg virus (MARV) can only be investigated in high containment laboratories, which is time consuming and expensive. To investigate the MARV life cycle under normal laboratory conditions, an infectious virus-like particle (VLP) system was developed. The infectious VLP system is based on the T7-polymerase driven synthesis of a MARV-specific minigenome that encodes luciferase and is transcribed and replicated by the simultaneously expressed MARV nucleocapsid proteins NP, VP35, L and VP30. Transcription of the minigenome resulted in luciferase activity and replication resulted in encapsidated minigenomes. The encapsidated minigenomes, together with the viral matrix proteins VP40 and VP24 and the surface glycoprotein (GP), formed VLPs at the plasma membrane. Among the released pleomorphic VLPs, filamentous particles of 200-400 nm in length showed the highest capacity to induce reporter activity upon infection of target cells. To characterize the infectious VLP system, the intracellular concentration of one of the components was titrated, while all others were held constant. Intracellular concentrations of nucleocapsid proteins that resulted in highest replication and transcription activities also yielded VLPs with the highest ability to induce luciferase activity in target cells. High intracellular levels of VP40 maximized the release of VLPs, but reduced their ability to induce luciferase activity in target cells. The intracellular concentration of GP positively correlated with its incorporation into VLPs and their infectivity. Finally, we demonstrated that the infectious VLP system was suitable for rapid screening of neutralizing antibodies directed against MARV.
高致病性马尔堡病毒(MARV)只能在高防护实验室中进行研究,这既耗时又昂贵。为了在正常实验室条件下研究 MARV 生命周期,开发了一种感染性病毒样颗粒(VLP)系统。该感染性 VLP 系统基于 T7 聚合酶驱动的 MARV 特异性小基因组的合成,该小基因组编码荧光素酶,并由同时表达的 MARV 核衣壳蛋白 NP、VP35、L 和 VP30 转录和复制。小基因组的转录导致荧光素酶活性,而复制则导致包封的小基因组。包封的小基因组与病毒基质蛋白 VP40 和 VP24 以及表面糖蛋白(GP)一起在质膜上形成 VLPs。在释放的多形 VLPs 中,长度为 200-400nm 的丝状颗粒在感染靶细胞时表现出最高的诱导报告活性的能力。为了表征感染性 VLP 系统,滴定了其中一种成分的细胞内浓度,而其他成分保持不变。导致最高复制和转录活性的核衣壳蛋白的细胞内浓度也产生了在靶细胞中诱导荧光素酶活性的最高能力的 VLPs。VP40 的高细胞内水平最大限度地提高了 VLPs 的释放,但降低了它们在靶细胞中诱导荧光素酶活性的能力。GP 的细胞内浓度与它掺入 VLPs 及其感染力呈正相关。最后,我们证明了感染性 VLP 系统适合快速筛选针对 MARV 的中和抗体。